Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surgery) according to HER2 and EGFR status: a randomized phase II trial

Trial Profile

Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surgery) according to HER2 and EGFR status: a randomized phase II trial

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine; Cisplatin; Epirubicin; Fluorouracil
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 08 Sep 2012 Planned number of patients changed from 350 to 480 as reported by European Clinical Trials Database.
    • 04 Jun 2012 Trial design presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top